Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Jan-Feb;11(1):59-67.
doi: 10.1310/hct1101-59.

Memantine for AIDS dementia complex: open-label report of ACTG 301

Yu Zhao  1 , Bradford A Navia, Christina M Marra, Elyse J Singer, Linda Chang, Joseph Berger, Ronald J Ellis, Dennis L Kolson, David Simpson, Eric N Miller, Stuart A Lipton, Scott R Evans, Giovanni Schifitto; Adult Aids Clinical Trial Group (ACTG) 301 Team
Collaborators, Affiliations
Randomized Controlled Trial

Memantine for AIDS dementia complex: open-label report of ACTG 301

Yu Zhao et al. HIV Clin Trials. 2010 Jan-Feb.

Abstract

Objective: To evaluate the long-term safety and efficacy of memantine use as treatment of HIV-associated cognitive impairment.

Background: The results of a 20-week, randomized, double-blind, placebo-controlled trial of memantine in HIV-infected participants with cognitive impairment (ACTG 301) were previously reported. We report the results of the up-to-60-week open-label phase following the double-blind phase.

Method: Participants received open-label memantine and were escalated to a 40 mg/day dose or their maximum tolerated dose in the double- blind phase. Adverse experiences were used to evaluate safety, and changes in the mean of eight neuropsychological test scores (NPZ-8) were used to evaluate efficacy.

Results: Ninety-nine participants entered the initial 12-week open-label phase and 45 in the additional 48-week extension. Twenty-seven participants reported severe adverse experiences. During the initial 12-week open-label phase, participants randomized to memantine in the double-blind phase had a statistically significant higher improvement in NPZ-8 compared to those randomized to placebo in the double-blind phase. No statistically significant NPZ-8 changes were detected during the 48-week extension.

Conclusion: Long-term use of memantine appears safe and tolerable. Future randomized studies with longer follow-up are necessary to establish efficacy of memantine for the treatment of HIV-associated cognitive impairment.

Trial registration: ClinicalTrials.gov NCT00000867.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CONSORT diagram.
See this image and copyright information in PMC

References

    1. Chang L, Lee PL, Yiannoutsos CT, et al. A multicenter in vivo proton-MRS study of HIV-associated dementia and its relationship to age. Neuroimage. 2004;23:1336–1347. - PubMed
    1. Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS. 1999;13:1249–1253. - PubMed
    1. Sacktor N, McDermott MP, Marder K, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J NeuroVirol. 2002;8:136–142. - PubMed
    1. Neuenburg JK, Brodt HR, Herndier BG, et al. HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31:171–177. - PubMed
    1. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2009 Dec 7; [Epub ahead of print]. PMID: 19996937. - PubMed

Publication types

Associated data